RVMD — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
$204.97
Market Cap
$43.93B
52W High
$224.31
52W Low
$42.78
ADV30
2,026,280
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -505,132,000 | -644,371,000 | 4,323,270,000 | 815,435,000 | 1,717,032,000 |
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,577,198,000
Investing CF
$-1,213,709,000
Financing CF
$3,262,040,000
CapEx
$-10,636,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,967,289,000
Inventory
—
Receivables
$0
ST Investments
$3,122,534,000
EBIT TTM
$-1,708,943,000
Pretax Income TTM
$-1,768,285,000
Interest Exp TTM
$59,342,000
Analysts
21
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | 1,631,297,000 | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | 2,265,204,000 | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | 1,826,194,000 | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | 685,188,000 | -224,401,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.95
Max Pain — expiry 2026-10-16
max pain strike: $190.00 · spot: $204.97 · call oi: 4,865 · put oi: 1,536
Expected Move to 2026-10-16:
±$17.58
(8.58%) —
implied range
$187.39 –
$222.55
· ATM straddle on $200.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIIB | BIOGEN INC. | $33.63B | $227.60 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| BNTX | BioNTech SE | $24.75B | $98.52 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| EXEL | EXELIXIS, INC. | $14.41B | $58.16 | — |
News headlines (Yahoo Finance, 1h cache)
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
2026-09-25 02:35 · Yahoo
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
2026-09-23 06:13 · Yahoo
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
2026-09-23 00:19 · Yahoo
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
2026-09-22 22:11 · Yahoo
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
2026-09-22 12:55 · Yahoo
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-18 13:00 · Yahoo
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
2026-09-17 08:20 · Yahoo
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
2026-09-16 12:30 · Yahoo
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
2026-09-14 20:05 · Yahoo
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
2026-09-12 00:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.